论文部分内容阅读
目的探讨卡培他滨联合奥沙利铂治疗胃癌患者术后淋巴结转移的治疗效果和不良反应发生情况。方法选择2008年7月至2010年7月间海安县中医院收治的58例胃癌术后淋巴结转患者。按治疗方式为两组:A组,卡培他滨+奥沙利铂;B组,顺铂+5-氟尿嘧啶。随访18个月比较两组的临床疗效及不良反应发生情况。结果 A、B组的临床获益率分别为55.1%、50.7%(P<0.05);病情控制率分别为89.6%、80.8%(P>0.05)。不良反应发生情况:B组的中性粒细胞减少率、胃肠道反应(呕吐、恶心)明显高于A组(P<0.05)。A、B组的1年生存率分别为61.2%、42.5%(P<0.05)。结论卡培他滨联合奥沙利铂治疗胃癌术后淋巴结转的效果较为满意,有较好的临床效果,不良反应较少,应在临床广泛推广。
Objective To investigate the curative effect and adverse reactions of capecitabine combined with oxaliplatin in the treatment of postoperative lymph node metastasis in patients with gastric cancer. Methods From July 2008 to July 2010 Hai’an County Hospital of Chinese medicine treatment of 58 cases of patients with postoperative lymph node metastasis. By treatment for the two groups: A group, capecitabine + oxaliplatin; B group, cisplatin + 5-fluorouracil. After 18 months of follow-up, the clinical efficacy and adverse reactions of the two groups were compared. Results The clinical benefit rates in group A and group B were 55.1% and 50.7%, respectively (P <0.05). The disease control rates were 89.6% and 80.8% respectively (P> 0.05). Adverse reactions occurred: B group of neutropenia, gastrointestinal reactions (vomiting, nausea) was significantly higher than the A group (P <0.05). The 1-year survival rates in groups A and B were 61.2% and 42.5%, respectively (P <0.05). Conclusion Capecitabine combined with oxaliplatin in the treatment of postoperative lymph node metastasis of gastric cancer is more satisfactory, with good clinical results, fewer adverse reactions, should be widely promoted in the clinic.